High-dose contrast-enhanced MRI in multiple sclerosis

T. Koudriavtseva, C. Pozzilli, C. Di Biasi, M. Iannilli, G. Trasimeni, C. Gasperini, C. Argentino, G. F. Gualdi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Contrast-enhanced MRI is effective for assessing disease activity in multiple sclerosis (MS) and may provide an outcome measure for testing the efficacy of treatment in clinical trials. To compare the sensitivity of high-dose gadolinium-HP-DO3A with that of a standard dose of gadolinium-DTPA, we studied 16 patients with relapsing-remitting MS in the acute phase of the disease. Each underwent two MRI examinations within at most 48 h. The initial MRI study was with a standard dose of gadolinium-DTPA (0.1 mmol/kg), and the second one an experimental dose of gadolinium-HP-DO3A (0.3 mmol/kg). No adverse effects were attributed to the contrast media. The high-dose study revealed more enhancing lesions than the standard-dose study (56 vs 38). This difference was found to be more relevant for infratentorial and small lesions. Furthermore, with the higher dose, there was a marked qualitative improvement in the visibility and delineation of the lesions.

Original languageEnglish
JournalNeuroradiology
Volume38
Issue numberSUPPL. 1
DOIs
Publication statusPublished - May 1996

Fingerprint

Multiple Sclerosis
Gadolinium DTPA
Relapsing-Remitting Multiple Sclerosis
Acute Disease
Contrast Media
Outcome Assessment (Health Care)
Clinical Trials
gadoteridol

Keywords

  • Gadolinium-HP-DO3A
  • High-dose contrast-enhanced magnetic resonance imaging Gadolinium-DTPA
  • Multiple sclerosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology
  • Radiological and Ultrasound Technology

Cite this

Koudriavtseva, T., Pozzilli, C., Di Biasi, C., Iannilli, M., Trasimeni, G., Gasperini, C., ... Gualdi, G. F. (1996). High-dose contrast-enhanced MRI in multiple sclerosis. Neuroradiology, 38(SUPPL. 1). https://doi.org/10.1007/s002340050909

High-dose contrast-enhanced MRI in multiple sclerosis. / Koudriavtseva, T.; Pozzilli, C.; Di Biasi, C.; Iannilli, M.; Trasimeni, G.; Gasperini, C.; Argentino, C.; Gualdi, G. F.

In: Neuroradiology, Vol. 38, No. SUPPL. 1, 05.1996.

Research output: Contribution to journalArticle

Koudriavtseva, T, Pozzilli, C, Di Biasi, C, Iannilli, M, Trasimeni, G, Gasperini, C, Argentino, C & Gualdi, GF 1996, 'High-dose contrast-enhanced MRI in multiple sclerosis', Neuroradiology, vol. 38, no. SUPPL. 1. https://doi.org/10.1007/s002340050909
Koudriavtseva T, Pozzilli C, Di Biasi C, Iannilli M, Trasimeni G, Gasperini C et al. High-dose contrast-enhanced MRI in multiple sclerosis. Neuroradiology. 1996 May;38(SUPPL. 1). https://doi.org/10.1007/s002340050909
Koudriavtseva, T. ; Pozzilli, C. ; Di Biasi, C. ; Iannilli, M. ; Trasimeni, G. ; Gasperini, C. ; Argentino, C. ; Gualdi, G. F. / High-dose contrast-enhanced MRI in multiple sclerosis. In: Neuroradiology. 1996 ; Vol. 38, No. SUPPL. 1.
@article{04947e44f3294cdeb3a856256125bcf3,
title = "High-dose contrast-enhanced MRI in multiple sclerosis",
abstract = "Contrast-enhanced MRI is effective for assessing disease activity in multiple sclerosis (MS) and may provide an outcome measure for testing the efficacy of treatment in clinical trials. To compare the sensitivity of high-dose gadolinium-HP-DO3A with that of a standard dose of gadolinium-DTPA, we studied 16 patients with relapsing-remitting MS in the acute phase of the disease. Each underwent two MRI examinations within at most 48 h. The initial MRI study was with a standard dose of gadolinium-DTPA (0.1 mmol/kg), and the second one an experimental dose of gadolinium-HP-DO3A (0.3 mmol/kg). No adverse effects were attributed to the contrast media. The high-dose study revealed more enhancing lesions than the standard-dose study (56 vs 38). This difference was found to be more relevant for infratentorial and small lesions. Furthermore, with the higher dose, there was a marked qualitative improvement in the visibility and delineation of the lesions.",
keywords = "Gadolinium-HP-DO3A, High-dose contrast-enhanced magnetic resonance imaging Gadolinium-DTPA, Multiple sclerosis",
author = "T. Koudriavtseva and C. Pozzilli and {Di Biasi}, C. and M. Iannilli and G. Trasimeni and C. Gasperini and C. Argentino and Gualdi, {G. F.}",
year = "1996",
month = "5",
doi = "10.1007/s002340050909",
language = "English",
volume = "38",
journal = "Neuroradiology",
issn = "0028-3940",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - High-dose contrast-enhanced MRI in multiple sclerosis

AU - Koudriavtseva, T.

AU - Pozzilli, C.

AU - Di Biasi, C.

AU - Iannilli, M.

AU - Trasimeni, G.

AU - Gasperini, C.

AU - Argentino, C.

AU - Gualdi, G. F.

PY - 1996/5

Y1 - 1996/5

N2 - Contrast-enhanced MRI is effective for assessing disease activity in multiple sclerosis (MS) and may provide an outcome measure for testing the efficacy of treatment in clinical trials. To compare the sensitivity of high-dose gadolinium-HP-DO3A with that of a standard dose of gadolinium-DTPA, we studied 16 patients with relapsing-remitting MS in the acute phase of the disease. Each underwent two MRI examinations within at most 48 h. The initial MRI study was with a standard dose of gadolinium-DTPA (0.1 mmol/kg), and the second one an experimental dose of gadolinium-HP-DO3A (0.3 mmol/kg). No adverse effects were attributed to the contrast media. The high-dose study revealed more enhancing lesions than the standard-dose study (56 vs 38). This difference was found to be more relevant for infratentorial and small lesions. Furthermore, with the higher dose, there was a marked qualitative improvement in the visibility and delineation of the lesions.

AB - Contrast-enhanced MRI is effective for assessing disease activity in multiple sclerosis (MS) and may provide an outcome measure for testing the efficacy of treatment in clinical trials. To compare the sensitivity of high-dose gadolinium-HP-DO3A with that of a standard dose of gadolinium-DTPA, we studied 16 patients with relapsing-remitting MS in the acute phase of the disease. Each underwent two MRI examinations within at most 48 h. The initial MRI study was with a standard dose of gadolinium-DTPA (0.1 mmol/kg), and the second one an experimental dose of gadolinium-HP-DO3A (0.3 mmol/kg). No adverse effects were attributed to the contrast media. The high-dose study revealed more enhancing lesions than the standard-dose study (56 vs 38). This difference was found to be more relevant for infratentorial and small lesions. Furthermore, with the higher dose, there was a marked qualitative improvement in the visibility and delineation of the lesions.

KW - Gadolinium-HP-DO3A

KW - High-dose contrast-enhanced magnetic resonance imaging Gadolinium-DTPA

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0029922756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029922756&partnerID=8YFLogxK

U2 - 10.1007/s002340050909

DO - 10.1007/s002340050909

M3 - Article

VL - 38

JO - Neuroradiology

JF - Neuroradiology

SN - 0028-3940

IS - SUPPL. 1

ER -